Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Sep 18, 2012
The Juvenile Bipolar Research Foundation is recruiting children to participate in a placebo controlled clinical trial in which they will receive four administrations of intranasal ketamine during a short, in-home protocol. Research leading up to this study delineated a particularly severe and treatment resistant form of the illness as well as a hypothesis of the neurological underpinnings of the disorder. Research informed investigators that ketamine, a drug known to reduce fear sensitization and lower core body temperature, may be an ideal treatment for the condition. A 4+ year pilot study produced a reduction of symptoms primary to the condition for those children who participated. The current IRB/FDA approved study is intended to document evidence of the observed treatment response. More information can be found on the JBRF website: www.jbrf.org